Stelexis Therapeutics LLC

Deerfield names two healthcare leaders as latest recipients of the ASH Peter Steelman Scholar Award NEW YORK, May 6, 2024 /PRNewswire/ -- Deerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second annual Acute Myeloid Leukemia (AML) Summit. The AML Summit convenes industry experts, leaders, and partners across healthcare to further advance research on this cancer of the bone marrow and blood. The AML Summit will recognize Emily Heikamp, M.D., Ph.D., M.Sc., and Sascha Haubner, M.D., as the 2023-2024 recipients of the ASH Peter Steelman Scholar Award for their academic achievements and contributions to AML research: Dr. Heikamp, a physician-scientist at Harvard Medical School, Boston Children's Hospital, and Dana-Farber Cancer Institute, specializes in epigenetic chromatin regulators in a rare, often fatal type of AML. Her research has identified novel molecular dependencies in this AML subtype, contributing to the development of targeted epigenetic drugs that are in early-phase clinical trials. Dr. Haubner is a physician-scientist specializing in chimeric antigen receptor (CAR) therapies for safe and efficient targeting of AML. As a senior research scientist at Memorial Sloan Kettering Cancer Center (MSKCC), he developed a novel combinatorial CAR T cell therapy (termed ADCLEC.syn1) which is currently undergoing clinical testing for AML patients at MSKCC. "Congratulations to Dr. Heikamp and Dr. Haubner, whose outstanding work embodies the legacy of the award itself, which honors former friend and Deerfield colleague, Peter Steelman, and his shared commitment to advancing healthcare," said Ross L. Levine, M.D., Senior Vice President, Memorial Hospital Translational Research at MSKCC, and Chair of The AML Summit. "We are thrilled to offer this award in partnership with ASH, which we hope will help support and pave the way for improved therapies for those affected by AML." As keynote speakers at this year's summit, Dr. Heikamp and Dr. Haubner will share more about their ongoing research efforts. Attendees will also hear from Simone Riedel, Ph.D., a Research Assistant Professor of Pediatrics (Oncology) at the University of Pennsylvania and the 2022 recipient of the ASH Peter Steelman Scholar Award. "Receiving this award as the inaugural recipient has been instrumental in further shaping and developing my research on epigenetic gene regulation over the past year. It has not only provided crucial financial support but also opened doors to invaluable relationships and resources within the research community," said Dr. Riedel. "I offer my heartfelt congratulations to both Dr. Heikamp and Dr. Haubner, as well as future recipients – I'm excited and optimistic about the future of our work and its potential to make a profound difference in the field." The AML Summit will be held on Tuesday, June 18 at Cure®, a healthcare innovation campus in New York City, and will showcase innovative clinical initiatives and cutting-edge research in AML. Additional featured guest speakers will include: Ross Levine, M.D., Leukemia Specialist & Physician-Scientist at Memorial Sloan Kettering Cancer Center; Chair of the AML Summit Simone Riedel, Ph.D., Research Assistant Professor of Pediatrics (Oncology) at Perelman School of Medicine at the University of Pennsylvania Emily Heikamp, M.D. Ph.D., M.Sc., Instructor in Pediatric Hematology – Oncology and Stem Cell Transplantation at Dana-Farber Cancer Institute Sascha Hubner, M.D., Senior Research Scientist | CAR Therapy at Memorial Sloan Kettering Cancer Center Scott Armstrong, M.D., Ph.D., President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Chairman, Department of Pediatric Oncology at Dana-Farber Cancer Institute; Associate Chief, Division of Hematology/Oncology at Boston Children's Hospital; and David G. Nathan Professor of Pediatrics at Harvard Medical School Kamal Menghrajani, M.D., M.Sc., White House Fellow Manuel Aivado, M.D., Ph.D., CEO of Stelexis Julian Adams, Ph.D., President and CEO of Stand Up To Cancer Jeff Spear, LLP About AML Adult acute myeloid leukemia (AML) is a cancer that occurs when bone marrow generates immature white blood cells that do not develop normally. Types of AML are defined by the maturity of the cancer cells at diagnosis, and the degree of their abnormalities. AML is the most common acute leukemia in adults. About 20,000 new AML diagnoses and 11,220 AML-related deaths, mostly in adults, will occur in the United States during 2024, the Centers for Disease Control and Prevention (CDC) estimates. Annually, about 75,266 people are living with AML in the United States, according to the CDC, and their five-year survival rate is 31.9 percent. About the ASH Peter Steelman Scholar Award Designed by Deerfield Management and Deerfield Foundation in partnership with ASH, the ASH-Peter Steelman Scholar Award supports exceptional academic research efforts focused on AML, and is part of ASH's Scholar Award program. For many researchers, the period between the completion of training and the establishment of an independent career can be a perilous and uncertain time. Since 1985, the ASH Scholar Award program has helped ease this difficult transition by providing support during that critical period required for the completion of training and achievement of status as an independent investigator. Recipients of the award will receive an extensive benefits package from the Deerfield Foundation, including: full funding for participation in the American Society of Hematology (ASH) Annual Meeting; an annual invitation, stipend, and research presentation opportunity at the AML Summit; biannual meetings with Deerfield Management's Oncology Working Group and ongoing collaboration with Deerfield Management; and ongoing access to Deerfield and Advancium Health Network's Science to the Street. Named in honor of former Deerfield Management Partner Peter Steelman, the award commemorates his lasting impact as a dedicated team member and a compassionate individual who embraced everyone with acceptance and kindness. In his tenure at Deerfield, Peter was instrumental in the creation of Deerfield's academic network, which today spans nearly 30 of the country's most prestigious institutions. Peter will always be missed and forever remembered. About Deerfield Foundation An affiliate of Deerfield Management, the Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to strive to improve health, accelerate innovation and promote human equity. Since its inception in 2007, the Foundation has formed numerous partnerships and invested in the advancement of children's health, from clinics in the South Bronx to Nepal. Funds are provided through employee contributions and directly from Deerfield's profits. About Deerfield Management Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways. For more information, please visit . Deerfield contact: Rachel Pelletier [email protected] (440) 409-6274 SOURCE Deerfield Management

Dr. Derrick Rossi Named Interim CEO NEW YORK, Sept. 9, 2022 /PRNewswire/ -- The New York Stem Cell Foundation (NYSCF) today announced the death of its Chief Executive Officer and Co-Founder, Susan L. Solomon, on September 8th, shortly after she had stepped down as CEO, after a long battle with ovarian cancer. Dr. Derrick Rossi, a member of the NYSCF Board of Directors and co-founder of Moderna Therapeutics, has been named Interim CEO of NYSCF. Continue Reading The New York Stem Cell Foundation today announced the death of its CEO and Co-Founder, Susan L. Solomon Tweet this Susan L. Solomon NYSCF is a New York-based non-profit organization that supports stem cell scientists around the world and operates the NYSCF Research Institute, the largest independent stem cell laboratory in the United States. As CEO, Ms. Solomon raised over $400M for stem cell research, helping to catalyze the field and transform the future of medical research. "This is the end of an incredible era for NYSCF," said Dr. Roy Geronemus, Chairman of the NYSCF Board of Directors. "Susan founded this organization in 2005, and guided it for over 17 years. She imagined the impossible and made it happen. I speak on behalf of the entire Board when I say that we will forever be grateful for all she did for NYSCF and for the field of stem cell research to advance better treatments and cures for patients everywhere. We are confident that Dr. Rossi as Interim CEO, and the rest of the NYSCF team, will continue the trajectory that Susan led us on to move NYSCF's mission forward. The Board has begun a search for a permanent CEO." A lawyer by training and a longtime entrepreneur and business executive, Ms. Solomon began her role as a health-care advocate in 1992 when one of her sons was diagnosed with type 1 diabetes. After conversations with clinicians and scientists, she identified stem cells as the most promising way to address unmet patient needs and felt an independent organization was needed to help translate cutting-edge stem cell research into clinical breakthroughs and cures for patients. She co-founded NYSCF in 2005. Since then, advances from NYSCF research have twice been named Time magazine's #1 scientific breakthrough of the year, and NYSCF-supported research has led to over 20 major clinical breakthroughs that are already or very soon bringing clinical treatments for devastating diseases. During her time as CEO, Ms. Solomon served on many Boards, including the College Diabetes Network and the Regional Plan Association, and received numerous awards, including the New York State Women of Excellence Award from the Governor of New York, the Triumph Award from the Brooke Ellison Foundation, and recognition as a Living Landmark from the New York Landmarks Conservancy. During a meeting earlier in the week with NYSCF staff to announce the CEO transition, Ms. Solomon relayed the following message: "Building NYSCF has been the privilege of a lifetime and I am incredibly proud of the contributions we have made to the field of stem cell research and developing new and more effective treatments and cures to improving the lives of patients. I am confident that our outstanding and dedicated leadership and staff will continue to move our programs forward under Derrick's leadership and that of our longtime COO/CFO Jeff Wallerstein while the Board conducts a search for my successor." "It has been a great privilege to serve on the NYSCF Board of Directors and I am honored to now serve as Interim CEO," said Dr. Rossi. "Since I first met Susan in 2010 and became a member of the NYSCF community, I have been in awe. Susan was a force of nature, a fierce and effective advocate for science and patients, and a true visionary. She was also a dear friend. Without question, Susan's and NYSCF's impact on science has been enormous and, quite frankly, unmatched. Though I wish that Susan could have continued her incredible and effective leadership of NYSCF for the next hundred years, I am nonetheless honored and ready to lead NYSCF over the coming months as we search for a permanent leader." Dr. Rossi, a biotechnology entrepreneur and stem cell scientist, is the co-founder of Moderna Therapeutics, and co-founder of Intellia Therapeutics, Magenta Therapeutics, and Stelexis Therapeutics. Until his retirement from academia, he was an Associate Professor at Harvard Medical School and Harvard University, and an investigator at Boston Children's Hospital where he led an academic team working on stem cell biology and regenerative medicine. In 2010, Derrick was named a NYSCF – Robertson Stem Cell Investigator and he joined the Board of Directors in 2020. His efforts in the development of cutting-edge technologies and new therapeutic strategies are at the forefront of regenerative medicine and biotechnology. Time magazine named Dr. Rossi as one of the 100 Most Influential People in the world (Time 100) in 2011. Dr. Rossi earned his B.Sc. and M.Sc. from University of Toronto, and his PhD from the University of Helsinki. Prior to founding NYSCF, Ms. Solomon had a diverse career spanning many decades. After graduating from New York University, she received her JD from Rutgers University School of Law while raising her eldest son as a single mother and serving as an editor of the Law Review. She began her career as an attorney at Debevoise & Plimpton. The work she was most passionate about was her pro bono work, including the representation of a woman suing the NYC Fire Department for sexual discrimination based on the firefighting qualification testing that was biased toward male applicants. She later continued her law career as counsel for Warner Amex Satellite Entertainment Corporation, a joint venture in the then-new industry of cable television to develop television networks, including MTV, Nickelodeon, and Showtime. After jobs at United Satellite Entertainment and CBS Productions, a film arm of CBS, Ms. Solomon joined MacAndrews & Forbes to help in the area of media acquisitions, and later APAX, formerly MMG Patricof and Company, another financial firm. Ms. Solomon subsequently joined Sony Corporation to establish and serve as President of a new radio network, Sony Worldwide Networks, which was the first to do internet radio broadcasting. She then moved on to her last media job as the founding CEO of Sothebys.com, where she helped to develop the first online auction platform. Prior to founding NYSCF in 2005, she started her own strategic management consulting firm, Solomon Partners LLC, through which she worked with a range of non-profit and media companies. Ms. Solomon is survived by her husband Paul Goldberger and three sons and daughters-in-law, Adam and Delphine Hirsh, Ben Goldberger and Melissa Rothberg, and Alex Goldberger and Carolyna De Laurentiis, and six grandchildren Thibeaux and Josephine Hirsh, Julian and Gabriel Goldberger, and Arlo and Celeste Goldberger. About The New York Stem Cell Foundation Research Institute The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 200 researchers at leading institutions worldwide, including the NYSCF – Druckenmiller Fellows, the NYSCF – Robertson Investigators, the NYSCF – Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in the development of pioneering stem cell technologies, including the NYSCF Global Stem Cell Array®, which is used to create cell lines for laboratories around the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. David McKeon 212-365-7440 [email protected] SOURCE The New York Stem Cell Foundation